Improving predictive capacity of models for universal influenza vaccine development
Improving predictive capacity of models for universal influenza vaccine development
批准号:
10672890
负责人:
RICHARD John WEBBY
金额:
$76.21万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-01 至 2024-07-31
关键词:
AddressAlgorithmsAnimal ModelAnimalsAntigensAntiviral AgentsAreaCaviaClinicalClinical ResearchCollaborationsDataData SetDevelopmentDoseEnsureExposure toFamily suidaeFerretsFundingFutureGoalsHamstersHumanImmuneImmune responseImmunityImmunizationImmunological ModelsImmunologicsIndividualInfantInfectionInfluenzaInfluenza A Virus, H3N2 SubtypeLassoLungMarriageMeasurementMeasuresMethodsModelingMonitorMusNational Institute of Allergy and Infectious DiseaseNatural HistoryNatureOrganOutcomeOutputPathogenesisPerformancePhysiologicalPopulationPre-Clinical ModelPredictive ValuePrimatesPropertyPublic HealthReagentRecording of previous eventsResearchSamplingSeasonsSerologyStrategic PlanningSymptomsSystemTelemetryTimeUnited StatesUpper respiratory tractVaccinatedVaccine ProductionVaccinesVirulenceVirusVirus ReplicationWhole Body Plethysmographyanimal dataanimal model developmentcohortefficacy testingflexibilityhuman datahuman modelimprintimprovedinfluenza virus vaccineinfluenzavirusinnovationmachine learning algorithmmouse developmentmultitasknext generationnovelporcine modelpreclinical evaluationproduct developmentresearch and developmentresponsesafety studyseasonal influenzatooltransmission processuniversal influenza vaccineuniversal vaccinevaccine candidatevaccine developmentvaccine effectivenessvaccine efficacyvaccine evaluation
中文摘要
人们很好地认识到需要改进和更具普遍保护性的流感疫苗。改进工作的核心是开发更能预测人类对免疫和/或感染的反应的动物模型。事实上,NIAID的通用流感疫苗战略计划强调了这一必要性。虽然动物模型可能永远无法完全预测人类的反应,但了解它们的全部优点和缺点并确定不同目的的最佳模型是重大的公共卫生需求,也是我们提出目标背后的科学前提。这些目标建立在我们广泛使用流感动物模型的基础上,旨在优化免疫印记的动物模型,改进疫苗效力测试,并确定保护和增强免疫反应的免疫相关性。我们的总体目标是提供卓越的临床前模型来支持通用流感疫苗的开发。我们将通过三个相互补充和相互关联的具体目标来实现这一目标,1)在动物模型中对重复暴露流感抗原的人类血清学反应进行最佳建模;2)改进雪貂流感挑战模型的量化性质;以及3)确定流感病毒引起的临床症状的血清学相关性。我们实现这些目标的能力是通过我们参与并与最近由NIAID资助的人类婴儿队列--Divinci研究--合作来支持的。我们将在三个动物模型中选择这些婴儿的流感抗原暴露情况,并比较免疫学数据集,以确定哪个最准确地反映人类的反应(目标1)。人类和动物数据集和样本的这种结合提供了一条创新的前进道路,并将提供一组独特的差异启动动物,用于使用原始机器学习算法(目标3)确定新的感染和免疫反应生理参数的免疫相关性(目标2)。
英文摘要
The need for improved and more universally protective influenza vaccines is well recognized. Central to efforts towards improvements is the development of animal models more predictive of the human response to immunization and/or infection. Indeed, this need has been highlighted by the NIAID Strategic Plan for a Universal Influenza Vaccine. While animal models may never be able to fully predict the human response, understanding their full strengths and weaknesses and identifying the optimal models for different purposes is a significant public health need and is the scientific premise behind our proposed objectives. These objectives, which are built upon our extensive use of influenza animal models, are to optimize animal modeling of immunologic imprinting, to improve vaccine efficacy testing, and to identify immune correlates of protection and boosting immune responses. Our overall goal is to provide superior preclinical models to support universal influenza vaccine development. We will achieve this goal through three complementary and interrelated specific aims, 1) optimal modeling of human serologic responses to repeat influenza antigen exposure in animal models; 2) improving the quantitative nature of the ferret influenza challenge model; and 3) defining serologic correlates of influenza virus induced clinical symptoms. Our ability to conduct these aims is supported through our participation in, and collaboration with, a recently NIAID-funded human infant cohort, the DIVINCI study. We will mirror the influenza antigen exposures of a selection of these infants in three animal models and compare immunologic data sets to identify which most accurately reflects the human response (Aim 1). This marriage of human and animal data sets and samples offers an innovative way forward and will provide a unique set of differentially primed animals with which to determine immune correlates of novel physiologic parameters of infection and immune responses (Aim 2) using original machine learning algorithms (Aim 3).
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/v15040946
发表时间:
2023-04-11
期刊:
Viruses
影响因子:
--
作者:
[Nichols JH, Williams EP, Parvathareddy J, Cao X, Kong Y, Fitzpatrick E, Webby RJ, Jonsson CB]
通讯作者:
Jonsson CB
Improving predictive capacity of models for universal influenza vaccine development
-
批准号:10224652
-
项目类别:
-
资助金额:$76.62万
-
财政年份:2020
-
负责人:RICHARD John WEBBY
-
依托单位:
Improving predictive capacity of models for universal influenza vaccine development
-
批准号:10439775
-
项目类别:
-
资助金额:$77.53万
-
财政年份:2020
-
负责人:RICHARD John WEBBY
-
依托单位:
MECHANISMS REGULATING AVIAN INFLUENZA VIRUS INFECTIONS IN HUMANS
-
批准号:10094050
-
项目类别:
-
资助金额:$19.09万
-
财政年份:2017
-
负责人:RICHARD John WEBBY
-
依托单位:
MECHANISMS REGULATING AVIAN INFLUENZA VIRUS INFECTIONS IN HUMANS
-
批准号:9244245
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2017
-
负责人:RICHARD John WEBBY
-
依托单位:
Therapeutic Monoclonal Antibodies to H5N1 Influenza
-
批准号:7134389
-
项目类别:
-
资助金额:$125.31万
-
财政年份:2006
-
负责人:RICHARD John WEBBY
-
依托单位:
Therapeutic Monoclonal Antibodies to H5N1 Influenza
-
批准号:7261358
-
项目类别:
-
资助金额:$122.6万
-
财政年份:2006
-
负责人:RICHARD John WEBBY
-
依托单位:
Therapeutic Monoclonal Antibodies to H5N1 Influenza
-
批准号:7666203
-
项目类别:
-
资助金额:$256.23万
-
财政年份:2006
-
负责人:RICHARD John WEBBY
-
依托单位:
Therapeutic Monoclonal Antibodies to H5N1 Influenza
-
批准号:7900034
-
项目类别:
-
资助金额:$343.54万
-
财政年份:2006
-
负责人:RICHARD John WEBBY
-
依托单位:
Therapeutic Monoclonal Antibodies to H5N1 Influenza
-
批准号:7478690
-
项目类别:
-
资助金额:$130.1万
-
财政年份:2006
-
负责人:RICHARD John WEBBY
-
依托单位:
海外基金